MarketPulse
N

$NHZHY

1 article found
0 positive
1 negative
0 neutral
BenzingaBenzinga··Bamboo Works

Chinese Cancer Screener Bets on Hong Kong IPO Despite Biotech Downturn

Wuhan Ammunition Life-tech pursues Hong Kong listing with doubled revenue but widened losses, facing 147x P/S valuation amid sector turmoil.
NHZHYBNRIPOHong Kong Stock Exchange